Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Apellis Pharmaceuticals, Inc. (APLS) had Revenue of $199.91M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$199.91M
Net Income	$-58.95M
Cost of Goods Sold	$29.72M
Gross Profit	$170.19M
Operating Expenses	$251.06M
Operating Income	$-51.14M
Non-Operating Income/Expense	$-7.50M
Pre-Tax Income	$-58.64M
Normalized Pre-Tax Income	$-58.64M
Income after Taxes	$-58.95M
Income from Continuous Operations	$-58.95M
Consolidated Net Income/Loss	$-58.95M
Normalized Income after Taxes	$-58.95M
EBIT	$-51.14M
EBITDA	$-50.16M
Weighted-Average Shares Outstanding (Basic)	126.14M
Weighted-Average Shares Outstanding (Diluted)	129.85M
Earnings per Share (EPS) (Basic)	$-0.46
Earnings per Share (EPS) (Diluted)	$-0.40
Balance Sheet Financials
Current Assets	$1.01B
Property, Plant, and Equipment	$1.71M
Long-Term Assets	$60.42M
Total Assets	$1.08B
Current Liabilities	$323.60M
Long-Term Debt	$361.66M
Long-Term Liabilities	$381.51M
Total Liabilities	$705.11M
Common Equity	$370.15M
Tangible Shareholders Equity	$370.15M
Shareholders Equity	$370.15M
Common Shares Outstanding	126.62M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$45.33M
Cash Flow from Investing Activities	$-0.31M
Cash Flow from Financial Activities	$8.88M
Beginning Cash	$412.61M
End Cash	$467.76M
Increase/Decrease in Cash	$55.15M
Stock-Based Compensation	$104.00M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.14
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.49
Debt to Equity Ratio	1.23
Gross Margin	85.13%
Operating Margin	-25.58%
EBIT Margin	-25.58%
EBITDA Margin	--
Pre-Tax Profit Margin	-29.33%
Profit Margin	-29.49%
Free Cash Flow	$45.01M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.19
Inventory Turnover	0.21
Receiveable Turnover	0.55
Days Sales in Receivables	164.87
Return on Equity	-15.93%
Return on Tangible Equity	-15.93%
Return on Assets	-5.48%
Return on Investments	-8.06%
Book Value Per Share	$2.92
Free Cash Flow per Share	$0.35
Operating Cash Flow per Share	$0.35

Data from Zacks Investment Research, Inc.